Laurent Chambonneau

Sanofi (France) — France

Medicine · Health Sciences

12h-index707citations17works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Mosquito-borne diseases and control(13), Viral Infections and Vectors(10), Malaria Research and Control(9), Vibrio bacteria research studies(3), Salmonella and Campylobacter epidemiology(2)

Publications17 total

Bayesian borrowing from historical control data in a vaccine efficacy trial
Pharmaceutical Statistics·2023Open Access
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials
The Journal of Infectious Diseases·2021· 6 citedOpen Access
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries
Transactions of the Royal Society of Tropical Medicine and Hygiene·2020· 4 citedOpen Access
Correlations between MN and PRNT<sub>50</sub> titers.
Figshare·2020Open Access
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
PLoS ONE·2020· 14 citedOpen Access
Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response
American Journal of Tropical Medicine and Hygiene·2019· 13 citedOpen Access
Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease
PLoS ONE·2018· 11 citedOpen Access
Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America
The Journal of Infectious Diseases·2017· 98 citedOpen Access
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America
The Journal of Infectious Diseases·2016· 50 citedOpen Access
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study
Vaccine·2015· 25 citedOpen Access
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects
Vaccine·2008· 132 cited
AGE-SPECIFIC PREVALENCE OF DENGUE ANTIBODIES IN BANGKOK INFANTS AND CHILDREN
The Pediatric Infectious Disease Journal·2008· 18 cited
Dengue Virus Infections in the First 2 Years of Life and the Kinetics of Transplacentally Transferred Dengue Neutralizing Antibodies in Thai Children
The Journal of Infectious Diseases·2006· 54 citedOpen Access
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)
Vaccine·2006· 66 cited
Combined Typhoid Fever and Hepatitis A Vaccine: Comparison of Immunogenicity and Safety to Concomitant Monovalent Vaccine over 3 Years
Journal of Travel Medicine·2006· 48 cited
A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults
Clinical Therapeutics·2004· 23 cited
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children
The Pediatric Infectious Disease Journal·2004· 145 cited

Frequent Co-authors

Zoe Moodie(7), Peter B. Gilbert(7), Ying Huang(6), Lindsay N. Carpp(6), Jean Lang(5), Michal Juraska(5), Youyi Fong(5), Yingying Zhuang(4), Carlos A. DiazGranados(4), Arunee Sabchareon(3), Pornthep Chanthavanich(3), Sutee Yoksan(3), Rémi Forrat(3), Krisana Pengsaa(3), Bruno Guy(3), Rafaele Dumas(3), Robert J. Small(3), Fernando Noriega(3), Jason Shao(3), Violette Sanchez(2)